Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
disitamab vedotin + dalpiciclib + exemestane
- Development stage
- Unknown
- Lead developer
- RemeGen
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy regimen is being investigated for the treatment of HER2-low, hormone receptor-positive (HR+) metastatic breast cancer. It consists of three distinct pharmacological agents: **disitamab vedotin**, a HER2-targeted antibody-drug conjugate (ADC) that delivers a microtubule-disrupting payload (monomethyl auristatin E, MMAE) directly to cancer cells; **dalpiciclib**, a selective small-molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) that halts cell cycle progression; and **exemestane**, a steroidal aromatase inhibitor that reduces estrogen production. The rationale for this triplet combination is to simultaneously inhibit HER2 signaling, the cell cycle, and the estrogen receptor pathway, potentially overcoming resistance mechanisms common in HR+/HER2-low breast cancer. The regimen is currently under evaluation in Phase 2 clinical trials sponsored by The First Affiliated Hospital of Wenzhou Medical University.
- Brand names
- AiditaiAi Rui Yi
- Other names
- RC48-ADCRC-48-ADCRC 48-ADCSHR-6390SHR6390SHR 6390
02
Targets
CYP19A1 (Aromatase)CDK4 (Cyclin-dependent kinase 4)CDK6 (Cyclin-dependent kinase 6)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on disitamab vedotin + dalpiciclib + exemestane.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on disitamab vedotin + dalpiciclib + exemestane.